Impact of COVID-19 on the incidence of cardiac arrhythmias in implantable cardioverter defibrillator recipients followed by remote monitoring.


Journal

Archives of cardiovascular diseases
ISSN: 1875-2128
Titre abrégé: Arch Cardiovasc Dis
Pays: Netherlands
ID NLM: 101465655

Informations de publication

Date de publication:
May 2021
Historique:
received: 20 01 2021
revised: 16 02 2021
accepted: 23 02 2021
pubmed: 6 6 2021
medline: 10 7 2021
entrez: 5 6 2021
Statut: ppublish

Résumé

The coronavirus disease 2019 (COVID-19) has been a fast-growing worldwide pandemic. We aimed to investigate the incidence of cardiac arrhythmias among a large French cohort of implantable cardioverter defibrillator recipients over the first 5 months of 2020. Five thousand nine hundred and fifty-four implantable cardioverter defibrillator recipients were followed by remote monitoring during the COVID-19 period (from 01 January to 31 May 2020). Data were obtained from automated remote follow-up of implantable cardioverter defibrillators utilizing the Implicity® platform. For all patients, the type of arrhythmia (atrial fibrillation, ventricular tachycardia or ventricular fibrillation), the number of ventricular arrhythmia episodes and the type of implantable cardioverter defibrillator-delivered therapy were recorded. A total of 472 (7.9%) patients presented 4917 ventricular arrhythmia events. An increase in ventricular arrhythmia incidence was observed after the first COVID-19 case in France, and especially during weeks #10 and #11, at the time of major governmental measures, with an increase in the incidence of antitachycardia pacing delivered therapy. During the 11 weeks before the lockdown order, the curve of the percentage of live-stream television coverage of COVID-19 information matched the ventricular arrhythmia incidence. During the lockdown, the incidence of ventricular arrhythmia decreased significantly compared with baseline (0.05±0.7 vs. 0.09±1.2 episodes per patient per week, respectively; P<0.001). Importantly, no correlation was observed between ventricular arrhythmia incidence and the curve of COVID-19 incidence. No changes were observed regarding atrial fibrillation/atrial tachycardia episodes over time. An increase in ventricular arrhythmia incidence was observed in the 2 weeks before the lockdown order, at the time of major governmental measures. Ventricular arrhythmia incidence decreased dramatically during the lockdown.

Sections du résumé

BACKGROUND BACKGROUND
The coronavirus disease 2019 (COVID-19) has been a fast-growing worldwide pandemic.
AIMS OBJECTIVE
We aimed to investigate the incidence of cardiac arrhythmias among a large French cohort of implantable cardioverter defibrillator recipients over the first 5 months of 2020.
METHODS METHODS
Five thousand nine hundred and fifty-four implantable cardioverter defibrillator recipients were followed by remote monitoring during the COVID-19 period (from 01 January to 31 May 2020). Data were obtained from automated remote follow-up of implantable cardioverter defibrillators utilizing the Implicity® platform. For all patients, the type of arrhythmia (atrial fibrillation, ventricular tachycardia or ventricular fibrillation), the number of ventricular arrhythmia episodes and the type of implantable cardioverter defibrillator-delivered therapy were recorded.
RESULTS RESULTS
A total of 472 (7.9%) patients presented 4917 ventricular arrhythmia events. An increase in ventricular arrhythmia incidence was observed after the first COVID-19 case in France, and especially during weeks #10 and #11, at the time of major governmental measures, with an increase in the incidence of antitachycardia pacing delivered therapy. During the 11 weeks before the lockdown order, the curve of the percentage of live-stream television coverage of COVID-19 information matched the ventricular arrhythmia incidence. During the lockdown, the incidence of ventricular arrhythmia decreased significantly compared with baseline (0.05±0.7 vs. 0.09±1.2 episodes per patient per week, respectively; P<0.001). Importantly, no correlation was observed between ventricular arrhythmia incidence and the curve of COVID-19 incidence. No changes were observed regarding atrial fibrillation/atrial tachycardia episodes over time.
CONCLUSIONS CONCLUSIONS
An increase in ventricular arrhythmia incidence was observed in the 2 weeks before the lockdown order, at the time of major governmental measures. Ventricular arrhythmia incidence decreased dramatically during the lockdown.

Identifiants

pubmed: 34088625
pii: S1875-2136(21)00089-9
doi: 10.1016/j.acvd.2021.02.005
pmc: PMC8141722
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

407-414

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Références

Front Psychol. 2020 Jul 03;11:1713
pubmed: 32719646
Circ Res. 2014 Mar 14;114(6):1004-21
pubmed: 24625726
N Engl J Med. 2020 Jul 30;383(5):496-498
pubmed: 32348640
Rev Esp Cardiol. 2005 May;58(5):587-91
pubmed: 15899201
J Cardiopulm Rehabil Prev. 2020 Sep;40(5):285-286
pubmed: 32804796
JACC Clin Electrophysiol. 2021 Jan;7(1):6-11
pubmed: 33478713
Lancet Public Health. 2020 Aug;5(8):e437-e443
pubmed: 32473113
Int J Environ Res Public Health. 2020 Jul 28;17(15):
pubmed: 32731509
Eur Heart J. 2021 Feb 1;42(5):520-528
pubmed: 33321517
Transl Psychiatry. 2020 Aug 20;10(1):291
pubmed: 32820171
N Engl J Med. 1996 Feb 15;334(7):413-9
pubmed: 8552142
Eur Heart J. 2020 Jun 1;41(32):3045-3054
pubmed: 32562486
J Clin Med. 2020 Aug 19;9(9):
pubmed: 32825068
Indian Pacing Electrophysiol J. 2014 Oct 06;14(5):230-2
pubmed: 25408562

Auteurs

Vincent Galand (V)

Department of Cardiology and Vascular Diseases, CHU de Rennes, 35000 Rennes, France. Electronic address: vincent.galand35@gmail.com.

Elliot Hwang (E)

Internal Medicine, St Joseph Mercy Hospital School, Ann Arbor, Michigan, United States.

Estelle Gandjbakhch (E)

Electrophysiology Unit, Cardiology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.

Frédéric Sebag (F)

Department of Medical Cardiology, Institut Mutualiste Montsouris, 75014 Paris, France.

Eloi Marijon (E)

Cardiology Department, Georges Pompidou European Hospital, 75015 Paris, France; DAI-PP Consortium, Georges Pompidou European Hospital, 75015 Paris, France.

Serge Boveda (S)

DAI-PP Consortium, Georges Pompidou European Hospital, 75015 Paris, France; Department of Cardiology, Clinique Pasteur, 31076 Toulouse, France.

Christophe Leclercq (C)

Department of Cardiology and Vascular Diseases, CHU de Rennes, 35000 Rennes, France.

Pascal Defaye (P)

Arrhythmia Department, Cardiology, University Hospital of Grenoble Alpes, 38043 Grenoble, France.

Arnaud Rosier (A)

DAI-PP Consortium, Georges Pompidou European Hospital, 75015 Paris, France; Department of Rhythmology, Hôpital Privé Jacques Cartier, Groupe GDS, 91300 Massy, France.

Raphaël Pedro Martins (RP)

Department of Cardiology and Vascular Diseases, CHU de Rennes, 35000 Rennes, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH